Canagliflozin Amputation Risk: What the Data Really Says and How to Stay Safe

If you take canagliflozin, also known by its brand name Invokana, you’ve likely heard the whispers. For years, headlines have linked this popular type 2 diabetes medication to a scary side effect: lower-limb amputation. It’s a heavy topic. No one wants to think about losing a toe or a foot while trying to manage their blood sugar. But here is the reality check: the risk is real, but it is often misunderstood, exaggerated, and highly specific to certain patients.

You are not alone in feeling confused. The medical community has spent nearly a decade untangling this issue. From initial FDA warnings to recent guideline updates, the story of canagliflozin and amputation risk is complex. This guide cuts through the noise. We will look at what the actual data says, why this drug behaves differently than others in its class, and exactly what steps you can take to protect your feet while keeping your diabetes under control.

The Origin of the Controversy: What the CANVAS Trial Showed

To understand the fear, we have to go back to 2017. That was when the results of the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) were published. This wasn’t just one study; it was a massive combination of two trials involving over 10,000 people with type 2 diabetes and cardiovascular disease.

The findings were startling. The study showed that people taking canagliflozin had roughly twice the risk of lower-limb amputation compared to those taking a placebo. Specifically, the rate was about 4.2 events per 1,000 patient-years for the 100 mg dose and 5.5 events per 1,000 patient-years for the 300 mg dose, versus 2.8 events for the placebo group. In response, the U.S. Food and Drug Administration (FDA) added a "boxed warning"-the strongest type of warning-to the drug’s label in June 2017.

But science rarely stops at one study. Over the next few years, more data came in. The CREDENCE trial, which focused on patients with diabetic kidney disease, did not show the same increased amputation risk. In fact, it highlighted significant benefits for heart and kidney health. Because of this new evidence, the FDA removed the boxed warning in January 2020. However, the warning didn’t disappear entirely. It remains in the "Warnings and Precautions" section of the prescribing information, advising doctors and patients to monitor for pain, sores, ulcers, and infections in the legs and feet.

Is It Just Canagliflozin? Comparing SGLT2 Inhibitors

This is where things get interesting. Canagliflozin belongs to a class of drugs called SGLT2 inhibitors. These medications work by helping your kidneys remove excess sugar from your body through urine. Other drugs in this class include empagliflozin (Jardiance) and dapagliflozin (Farxiga).

If the amputation risk were a problem with the entire class, we would see it in all these drugs. But we don’t. Large studies like EMPA-REG OUTCOME (for empagliflozin) and DECLARE-TIMI 58 (for dapagliflozin) did not show a significant increase in amputation risk. A 2023 meta-analysis confirmed this pattern: only canagliflozin was associated with a statistically significant increase in limb amputation.

Why does canagliflozin stand out? Experts believe it may be related to how strongly it lowers blood pressure and body weight compared to other SGLT2 inhibitors. A drop in blood pressure might reduce blood flow to the extremities, potentially worsening pre-existing peripheral artery disease (PAD). This suggests the risk isn't random-it’s likely concentrated in patients who already have poor circulation or nerve damage.

Who Is Actually at Risk?

Understanding your personal risk profile is crucial. The absolute risk of amputation for the average person taking canagliflozin is low. Studies estimate the number needed to harm (NNH) at around 556. This means that for every 556 patients treated for one year, one additional amputation might occur due to the drug. While that sounds small, it matters if you are in a high-risk group.

You are considered higher risk if you have:

• Peripheral Artery Disease (PAD): Narrowed arteries that reduce blood flow to your limbs. PAD affects 20-30% of people with type 2 diabetes.
• Diabetic Neuropathy: Nerve damage that causes loss of sensation in your feet. If you can’t feel a blister forming, it can turn into an ulcer quickly.
• History of Foot Ulcers or Amputations: Past issues predict future problems. Recurrence rates for foot ulcers are high without proper care.
• Chronic Kidney Disease: Often co-exists with vascular issues.
• Current Tobacco Use: Smoking severely damages blood vessels.

If you have two or more of these risk factors, many clinicians, including protocols from the University of Michigan, suggest avoiding canagliflozin altogether. Instead, they recommend switching to another SGLT2 inhibitor like empagliflozin or dapagliflozin, which offer similar heart and kidney benefits without the same amputation signal.

Prevention Strategies: Protecting Your Feet

If you are currently taking canagliflozin and want to stay on it because it works well for your blood sugar, you don’t necessarily have to stop. You just need to be proactive. Prevention is far more effective than treatment when it comes to foot complications.

1. Daily Foot Inspections: Make it a habit. Check your feet every day for redness, swelling, blisters, cuts, or sores. Use a mirror if you can’t see the bottoms of your feet. If you have neuropathy, rely on sight since you can’t rely on feeling.
2. Professional Exams: See a podiatrist or your primary care doctor for a comprehensive foot exam at least once a year, or more often if you have risk factors. They should check your pulses, sensation, and skin integrity.
3. Ankle-Brachial Index (ABI) Testing: The American Diabetes Association’s 2025 Standards of Care now recommend routine ABI measurements before starting canagliflozin in patients with cardiovascular risk factors. An ABI score below 0.9 indicates peripheral artery disease and may be a reason to choose a different medication.
4. Proper Footwear: Wear well-fitting shoes and socks. Avoid walking barefoot. Diabetic shoes can provide extra cushioning and protection against pressure points.
5. Immediate Action: Report any new pain, tenderness, or infection in your legs or feet to your doctor immediately. Do not wait. Early intervention can prevent a minor sore from becoming a major wound.

Real-World Perspectives and Future Outlook

What do patients actually experience? Real-world data from forums like PatientsLikeMe shows that while most users tolerate canagliflozin well, a small percentage report foot problems. One user shared, "After 18 months on Invokana, my podiatrist found a non-healing ulcer that led to a toe amputation-my endocrinologist immediately switched me to Jardiance." Another reported three years of use with no issues and significant A1c improvement. These stories highlight the variability in individual response.

Looking ahead, research continues. The ongoing FOOT-STEP trial aims to determine if structured foot care protocols can mitigate amputation risk in high-risk patients. Additionally, Janssen Pharmaceuticals is developing a modified-release formulation of canagliflozin (INVOKANA XR), which may alter how the drug affects blood flow and potentially reduce risk. Until then, the focus remains on careful patient selection and vigilant monitoring.

Remember, canagliflozin is still listed on the World Health Organization’s Model List of Essential Medicines. It is a powerful tool for managing diabetes, protecting the heart, and preserving kidney function. The key is using it wisely, knowing your risks, and staying informed.